Focus

Drug Discovery Investors: Angels and VC Firms

The RaiseHunt database lists 4,683 Drug Discovery investors: 239 angel investors and 4,444 people at 1,313 firms. Most list Seed and Series A among their stages; the largest hubs are New York, San Francisco and Boston.

Strongest in New York, San Francisco and Boston

Common stages: Seed and Series A

4,683
Drug Discovery investors
239
Angel investors
4,444
People at VC/PE firms
1,313
Firms tagged

Skip the browsing. Let AI find your ideal investors in one minute.

Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.

4,683 Drug Discovery investors

Showing 1-20

Filters
Matt McIlwain
Matt McIlwain

Managing Director

Seattle, United States
Angel
AIHealthcare
View profile
Ross Youngs
Ross Youngs

CEO & Co-Founder

Dublin, United States
AngelOperator angel
ClimateHealthcare
View profile
Jack Hidary
Jack Hidary

Chief Executive Officer

Palo Alto, United States
AngelOperator angel
AIClimate
View profile
George Mills
George Mills

Director - Direct and Co-investments

London, United Kingdom
Angel
AIEnergy
View profile
Santa Monica, United States
AngelOperator angel
FinTechHealthcare
View profile
London, United Kingdom
AngelOperator angel
AIHealthcare
View profile
Hanover, United States
AngelOperator angel
Healthcare
View profile
New York, United States
Angel
FinTechHealthcare
View profile
Michael Jin
Michael Jin

Managing Partner

Palo Alto, United States
AngelOperator angel
AIClimate
View profile
Matthew De Silva
Matthew De Silva

Venture Partner

Chicago, United States
AngelOperator angel
AIHealthcare
View profile
Pablo Legorreta
Pablo Legorreta

Founder & Chief Executive Officer

New York City, United States
AngelOperator angel
Healthcare
View profile
Henry Kravis
Henry Kravis

Founding Partner

New York, United States
Angel
AIFinTech
View profile
Peter Keen
Peter Keen

Independent Investment Committee member

Cambridge, United Kingdom
Angel
FinTechHealthcare
View profile
Manchester, United Kingdom
Angel
FinTechHardware
View profile
Demis Hassabis
Demis Hassabis

Co-Founder & CEO

London, United Kingdom
AngelOperator angel
AIHealthcare
View profile
Dan Schultz
Dan Schultz

Head of Originations

Boston, United States
Angel
ConsumerFinTech
View profile
Margo Georgiadis
Margo Georgiadis

Managing Partner

San Francisco, United States
AngelOperator angel
AIHealthcare
View profile
Mike Novogratz
Mike Novogratz

CEO of Galaxy Digital + Systems Changer

New York, United States
AngelOperator angel
FinTechHealthcare
View profile
Ronjon Nag
Ronjon Nag

Founder and President

Palo Alto, United States
AngelOperator angel
AIHealthcare
View profile
Evan Schwartz
Evan Schwartz

Board Observer

Boston, United States
AngelOperator angel
AIHealthcare
View profile

900 of 4,683 Drug Discovery investors, A to Z

Grouped by first letter. Name and profile link only, the detailed rows are in the table above.
Show

A84

B45

C56

D60

E26

F20

G27

H28

I13

J108

K39

L33

M88

N27

O7

P40

Q3

R53

S67

T27

U2

V15

W14

X2

Y6

Z10

Frequently asked questions

How many Drug Discovery investors are on RaiseHunt?

RaiseHunt currently lists 4,683 Drug Discovery investors.

Are Drug Discovery investors angels or funds?

Both. 239 are angel investors putting in their own money, and 4,444 are people making investment decisions at 1,313 firms.

Where are most Drug Discovery investors based?

The largest concentrations are in New York, San Francisco and Boston.

What stage do Drug Discovery investors invest at?

Most list Seed and Series A among the rounds they take part in.

How do I contact Drug Discovery investors?

Every profile shows whether an email address is on file. The addresses themselves, along with AI matching and outreach, are in the RaiseHunt app.

Is the list of Drug Discovery investors free to browse?

Yes. The directory and every profile page are free to read. Matching your own startup against them requires an account.

Do Drug Discovery investors only back Drug Discovery companies?

No. A focus area is a signal of interest, not a restriction. Investors usually list several, and the useful question is whether their existing portfolio looks like the kind of company you are building.

How many Drug Discovery investors should I contact?

Far more than feels comfortable. Response rates on cold outreach are low even when the fit is good, so a list of a handful of perfect names tends to stall. Build a long list, sort it by how well each one matches what you are building, and work down it in batches rather than sending everything at once.

What should I have ready before reaching out?

A short deck, a one-paragraph description of what you do and who it is for, and a clear number for how much you are raising. Investors read the first two lines before they decide whether to open the deck, so those lines matter more than the rest of the document.

Does a warm introduction still matter?

It helps, mostly because it moves your email out of a crowded inbox. It is not a requirement. A cold message that shows you understand what someone has already backed, and why your company fits that pattern, gets read more often than a vague introduction from a distant contact.

How do I know which Drug Discovery investors are a fit?

Look at what they have already funded rather than what their profile says they like. Stage matters most, then sector, then geography. An investor who has never funded anything at your stage is unlikely to start with you, however well the sector lines up.

How long does raising a round usually take?

Longer than most first-time founders plan for. The work splits into building the list, running outreach, taking meetings, and closing, and each stage can stretch. Start before you need the money, not when the runway is short.

Data: RaiseHunt investor dataset · Snapshot 26 September 2026 · How this data is built · Report a correction or request removal